Acute Interstitial Nephritis Associated with the Use of Mesalazine in Inflammatory Bowel Disease

Frandsen, Niels Erik; Saugmann, Søren; Marcussen, Niels

doi:10.1159/000064461

Cited by 35 publications

(25 citation statements)

References 6 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 summarizes the 23 biopsy-proven case reports of this complication published in the English literature over the past 13 years. The mean age at diagnosis was 33 years, with the current patient and that of Frandsen et al [14] being the youngest reported patients at 18 years of age. Of the reported patients, 26% had Crohn disease, while 74%, including our patient, had ulcerative colitis.…”

Section: Discussionmentioning

confidence: 44%

See 1 more Smart Citation

Interstitial nephritis from mesalazine: case report and literature review

Arend

Springate

2004

Pediatric Nephrology

View full text Add to dashboard Cite

We report a new case of biopsy-confirmed mesalazine-induced interstitial nephritis in an 18-year-old male with ulcerative colitis. His renal function improved with drug discontinuation and corticosteroid treatment. An English literature review revealed an additional 22 cases of this complication that, taken together, showed (1) a male predominance, (2) an absence of specific symptoms or findings on urinalysis, (3) a 61% frequency of residual chronic renal insufficiency with 13% of patients developing end-stage renal disease, and (4) an apparent favorable response to steroid therapy. We conclude that patients receiving 5-aminosalicylates should be routinely monitored with serum creatinine measurements to prevent this uncommon but potentially serious adverse drug reaction.

show abstract

Section: Discussionmentioning

confidence: 44%

“…Over the past decade, more than 30 cases of interstitial nephritis associated with this medication have been described worldwide [1,2,3,4,5,6,7,8,9,10,11,12,13,14]. Only 1 such patient has been 18 years of age or less.…”

Section: Introductionmentioning

confidence: 99%

Interstitial nephritis from mesalazine: case report and literature review

Arend

Springate

2004

Pediatric Nephrology

View full text Add to dashboard Cite

show abstract

“…[18,19] Ulcerative colitis is a disease that occurs in human colon, where thousands of microorganisms reside. But it is not significantly found in germ-free animals.…”

Section: Discussionmentioning

confidence: 99%

Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: a placebo controlled study

Vejdani¹,

Bahari²,

Zadeh³

et al. 2017

Indian J Med Sci

View full text Add to dashboard Cite

Background: The effects of probiotics on ulcerative colitis has still remained a contraversy. The aim of this study was to assess the effects of Lactobacillus casei strain ATCC PTA-3945 in treating ulcerative colitis. Materials and Methods: Thirty four patients with mild to moderately active ulcerative colitis randomly received a probiotic preparation of L. casei strain ATCC PTA-3945 (n = 17) or its placebo (n = 17) plus conventional medical therapy for their active disease. After a maximum of 2 months, remitted patients were again randomised to receive L. casei strain ATCC PTA-3945 or placebo, and also maintained on mesalazine or sulfasalazine tablets for a maximum of 6 months. Results: The numbers of patients achieving remission did not statistically differ between probiotic and placebo groups (82% vs. 76% at intention to treat analysis [P = 1.00], and 100% vs. 81.2% at per-protocol analysis [P = 0.23], respectively). The mean time to clinical remission were 25 days and 32 days in probiotic and placebo groups, respectively (P = 0.11). Relapse rates also did not significantly differ between probiotic and placebo groups (14.3% vs. 26.7% at ITT analysis [P = 0.65] and 16.7% vs. 33.3% [P = 0.64], respectively). Mean time to relapse were 96 days and 74 days in the probiotic and the placebo group, respectively (P = 0.51). Conclusion: The results of this preliminary study showed no significant effect by using L. casei strain ATCC PTA-3945 probiotic in the treatment of ulcerative colitis patients.

show abstract

“…The risk of side effects such as interstitial nephritis caused by systemic absorption of 5-ASA restrains the use of high doses for treatment [Frandsen et al 2002;Riley et al 1992;Staerk Laursen et al 1990]. About 30% of an oral administration dose of 5-ASA (coated, timereleased or azo-bound) is absorbed, and can potentially cause side effects [Klotz, 1985].…”

Section: In Vivo Investigationmentioning

confidence: 99%

Possible interactions between dietary fibres and 5-aminosalicyclic acid

Henriksen

Hansen

Nordgaard-Lassen

et al. 2009

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Abstract:Background: Potentially, a binding of 5-aminosalicyclic acid (5-ASA) to dietary fibres could reduce the systemic absorption and increase the intraluminal amount. The purposes of the study were to investigate if: (1) dietary fibres can bind 5-ASA in vitro, and (2) consumption of dietary fibres is related to disease activity in patients with ulcerative colitis (UC) treated with 5-ASA. Methods: In vitro: 15 g of Ispaghula Husk, wheat bran, citrus-pectin, or wheat flour were incubated in a 37 C buffered solutions of 5-ASA (1 g/l) for 3 hours at pH 6 and 7. The concentrations of 5-ASA were determined before and after the incubation using HPLC. In vivo: patients with UC were interviewed two to three times during 6 months. The fibre consumption was estimated and related to the disease activity (CAI, CRP, Faecal-calprotectin) and quality of life (IBDQ). Results: In vitro: 5-ASA was bound to Ispaghula Husk (5.310.0 mg/g) and wheat bran (4.65.5 mg/g), and to a minor degree to citrus-pectin. No differences were found in relation to pH. In vivo: 29 patients completed the scheduled interviews. No significant changes in fibre consumption were observed over time; however, patients consuming a diet high in fibre (>20 g/ day) had significantly lower CRP (p <0.01) and faecal-calprotectin (p <0.01) than those consuming less fibre (<20 g/dg). Conclusions: Patients with a high intake of fibre had a lower disease activity than those with low intake. Ispaghula Husk bound 5-ASA in vitro, independent of pH. The effect might be clinically relevant in patients with UC treated with 5-ASA.

show abstract

Acute Interstitial Nephritis Associated with the Use of Mesalazine in Inflammatory Bowel Disease

Cited by 35 publications

References 6 publications

Interstitial nephritis from mesalazine: case report and literature review

Interstitial nephritis from mesalazine: case report and literature review

Effects of lactobacillus casei probiotic on mild to moderate ulcerative colitis: a placebo controlled study

Possible interactions between dietary fibres and 5-aminosalicyclic acid

Contact Info

Product

Resources

About